Dose-Response Modifiers in Radiation Therapy

Clinical Radiation Oncology: Third Edition

Volumn , Issue , 2012, Pages 53-64

  Horsman, Michael R ^a   Lindegaard, Jacob C ^a   Grau, Cai ^a   Nordsmark, Marianne ^a   Overgaard, Jens ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84967109535     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-1637-5.00003-1     Document Type: Chapter

References (50)

1. Schwarz G über Desensibiliserung gegen Röntgen-und Radiumstrahlen. Munchener Medizinische Wochenschrift 1909, 24:1-2.
2. Müller C Eine neue Behandlungsmethode bösartiger Geschwülste. Munchener Medizinische Wochenschrift 1910, 28:1490-1493.
3. Gray LH, Conger AD, Ebert M, et al. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953, 26:638-648.
4. Thomlinson RH, Gray LH The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955, 9:539-549.
5. Tannock IF The relationship between cell proliferation and the vascular system in a transplanted mouse mammary tumour. Br J Cancer 1968, 22:258-273.
6. Chaplin DJ, Olive PL, Durand RE Intermittent blood flow in a murine tumor. Radiobiological effects. Cancer Res 1987, 47:597-601.
7. Horsman MR Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours. Acta Oncol 1995, 34:571-587.
8. Moulder JE, Rockwell S Hypoxic fractions of solid tumour. Int J Radiat Oncol Biol Phys 1984, 10:695-712.
9. Horsman MR Hypoxia in tumours: Its relevance, identification and modification. Current topics in clinical radiobiology of tumours 1993, 99-112. Springer-Verlag, Berlin. H.P. Beck-Bornholdt (Ed.).
10. Horsman MR Measurement of tumour oxygenation. Int J Radiat Oncol Biol Phys 1998, 42:701-704.
11. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005, 77:18-24.
12. Overgaard J, Horsman MR Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 1996, 6:10-21.
13. Suit HD, Marshall N, Woerner D Oxygen, oxygen plus carbon dioxide, and radiation therapy of a mouse mammary carcinoma. Cancer 1972, 30:1154-1158.
14. Rojas A Radiosensitization with normobaric oxygen and carbogen. Radiother Oncol 1991, 20(Suppl. 1):65-70.
15. Overgaard J Sensitization of hypoxic tumour cells-clinical experience. Int J Radiat Biol 1989, 56:801-811.
16. Mendenhall WM, Morris CG, Amdur RJ, et al. Radiotherapy alone or combined with carbogen breathing for squamous cell carcinoma of the head and neck. Cancer 2005, 104:332-337.
17. Chaplin DJ, Horsman MR, Siemann DW Further evaluation of nicotinamide and carbogen as a strategy to reoxygenate hypoxic cells in vivo. Importance of nicotinamide dose and pre-irradiation breathing time. Br J Cancer 1993, 68:269-273.
18. Adams GE, Cooke MS Electron-affinic sensitization. I. A structural basis for chemical radiosensitizers in bacteria. Int J Radiat Biol 1969, 15:457-471.
19. Asquith JC, Watts ME, Patel K, et al. Electron-affinic sensitization V. Radiosensitization of hypoxic bacteria and mammalian cells in vitro by some nitroimidazoles and nitropyrazoles. Radiat Res 1974, 60:108-118.
20. Overgaard J Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res 1994, 6:509-518.
21. Overgaard J, Sand Hansen H, Overgaard M, et al. A randomised double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish head and neck cancer study (DAHANCA) protocol 5-85. Radiother Oncol 1998, 46:135-146.
22. Dobrowsky W, Huigol NG, Jayatilake RS, et al. Ak-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cervical cancer. Results of an IAEA multicentre randomized trial. Radiother Oncol 2007, 82:24-29.
23. Grau C, Overgaard J Significance of haemoglobin concentration for treatment outcome. Medical radiology: blood perfusion and microenvironment of human tumours 1998, 101-112. Springer-Verlag, Heidelberg. M. Molls, P. Vaupel (Eds.).
24. Thomas GM Raising hemoglobin. An opportunity for increasing survival?. Oncology 2002, 63:19-28.
25. Stuben G, Pottgen C, Knuhmann K, et al. Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J Radiat Oncol Biol Phys 2003, 55:1358-1362.
26. Hoskin PJ, Robinson M, Slevin N, et al. Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer. J Clin Oncol 2009, 27:5751-5756.
27. Hoskin PJ, Rojas A, Saunders MI Accelerated radiotherapy, carbogen, and nicotinamide (ARCON) in the treatment of advanced bladder cancer. Mature results of a phase II nonrandomized study. Int J Radiother Oncol Biol Phys 2009, 73:1425-1431.
28. McKeown SR, Cowen RL, Williams KJ Bioreductive drugs. From concept to clinic. Clin Oncol 2007, 19:427-442.
29. Fidler IJ, Langley RR, Kerbel RS, Ellis LM Angiogenesis. Cancer principles and practice of oncology 2005, 129-137. Lippincott Williams & Wilkins, Philadelphia. ed 7. V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.).
30. Horsman MR, Siemann DW Pathophysiological effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 2006, 66:11520-11539.
31. Patt HM, Tyree EB, Straub RL, Smith DE Cysteine protection against X irradiation. Science 1949, 110:213-214.
32. Yuhas JM Protective drugs in cancer therapy. Optimal clinical testing and future directions. Int J Radiat Oncol Biol Phys 1982, 8:513-517.
33. Lindegaard JC, Grau C Has the outlook improved for amifostine as a clinical radioprotector?. Radiother Oncol 2000, 57:113-118.
34. Savoye C, Swenberg C, Hugot S, et al. Thiol WR-1065 and disulphide WR-33278, two metabolites of the drug ethyol (WR-2721), protect DNA against fast neutron-induced strand breakage. Int J Radiat Biol 1997, 71:193-202.
35. Denekamp J, Michael BD, Rojas A, Stewart FA Radioprotection of mouse skin by WR-2721. The critical influence of oxygen tension. Int J Radiat Oncol Biol Phys 1982, 8:531-534.
36. Travis EL The oxygen dependence of protection by aminothiols. Implications for normal tissues and solid tumors. Int J Radiat Oncol Biol Phys 1984, 10:1495-1501.
37. Winczura P, Jassem J Combined treatment with cytoprotective agents and radiotherapy. Cancer Treat Rev 2010, 36(3):268-275.
38. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000, 18:3339-3345.
39. Adams GE, Barnes DW, du-Boulay C, et al. Induction of hypoxia in normal and malignant tissues by changing the oxygen affinity of hemoglobin-implications for therapy. Int J Radiat Oncol Biol Phys 1986, 12:1299-1302.
40. Keidan AJ, Franklin IM, White RD Effect of BW12C on oxygen affinity of haemoglobin in sickle cell disease. Lancet 1986, 1:831-834.
41. Honess DJ, Hu DE, Bleehen NM BW12C. Effects on tumour hypoxia, tumour radiosensitivity and relative tumour and normal tissue perfusion in C3H mice. Br J Cancer 1991, 64:715-722.
42. Roughton FJW, Darling RC The effect of carbon monoxide on the oxyhemoglobin dissociation curve. Am J Phys 1944, 141:17-31.
43. 2) on the in vivo radiation response of a murine sarcoma. Int J Radiat Oncol Biol Phys 1977, 2:903-911.
44. Ward A, Clissold SP Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987, 34:50-97.
45. Lee I, Kim JH, Levitt SH, Song CW Increases in tumor response by pentoxifylline alone or in combination with nicotinamide. Int J Radiat Oncol Biol Phys 1992, 22:425-429.
46. Dion MW, Hussey DH, Osborne JW The effect of pentoxifylline on early and late radiation injury following fractionated irradiation in C3H mice. Int J Radiat Oncol Biol Phys 1989, 17:101-107.
47. Hendry JH Biological response modifiers and normal tissue injury after irradiation. Semin Radiat Oncol 1994, 4:123-132.
48. Rubin P, Johnston CJ, Williams JP, et al. A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys 1995, 33:99-109.
49. Hill RP, Marie-Egyptienne DT, Hedley DW Cancer stem cells, hypoxia and metastasis. Semin Radiat Oncol 2009, 19:106-111.
50. Baumann M, Krause M, Hill R Exploring the role of cancer stem cells in radioresistance. Nat Revs Cancer 2008, 8:545-554.